{"filing":{"accession_number":"0001193125-26-399377","cik":"0001590877","ticker":"RGNX","company_name":"REGENXBIO Inc.","form":"8-K","filing_date":"2026-09-23","report_date":"2026-09-23","primary_document":"rgnx-20260923.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312526399377/rgnx-20260923.htm"},"events":[{"id":34569,"run_id":31814,"accession_number":"0001193125-26-399377","anchor_item_number":"1.01","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"summary":"REGENXBIO settled material patent infringement litigation with Sarepta Therapeutics and Catalent regarding U.S. Patents 10,526,617 and 11,680,274 related to SRP-9001 (ELEVIDYS). The settlement involves a $39.0 million payment to the Company and termination with prejudice of all ongoing patent litigation, along with mutual covenants not to sue. This is a material litigation settlement that would affect a reasonable investor's assessment of the Company's patent portfolio and financial position.","company_name":"REGENXBIO Inc.","ticker":"RGNX","filing_date":"2026-09-23","form":"8-K","submitted_at":null,"items":[{"id":38326,"accession_number":"0001193125-26-399377","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"REGENXBIO settled material patent infringement litigation with Sarepta Therapeutics and Catalent regarding U.S. Patents 10,526,617 and 11,680,274 related to SRP-9001 (ELEVIDYS). The settlement involves a $39.0 million payment to the Company and termination with prejudice of all ongoing patent litigation, along with mutual covenants not to sue. This is a material litigation settlement that would affect a reasonable investor's assessment of the Company's patent portfolio and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:09:01.016997+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38326,"accession_number":"0001193125-26-399377","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"material_litigation","event_domain":"legal","is_material":true,"confidence":0.92,"reasoning":"REGENXBIO settled material patent infringement litigation with Sarepta Therapeutics and Catalent regarding U.S. Patents 10,526,617 and 11,680,274 related to SRP-9001 (ELEVIDYS). The settlement involves a $39.0 million payment to the Company and termination with prejudice of all ongoing patent litigation, along with mutual covenants not to sue. This is a material litigation settlement that would affect a reasonable investor's assessment of the Company's patent portfolio and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-23T20:09:01.016997+00:00","company_name":"REGENXBIO Inc.","ticker":"RGNX","filing_date":"2026-09-23"}]}